{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:53:58Z","timestamp":1790776438119,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The COVID-19 pandemic was managed in Aotearoa New Zealand (NZ) by a COVID-19 elimination policy, involving border closure and an initial national lockdown. This was different to most other countries including Northern Ireland (NI) and the Netherlands (NED). We quantify the effect of these policies on the diagnosis of three major cancers, comparing NZ with these two European countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Data from NED, NZ and NI population-based cancer registries were used to assess trends in all pathologically diagnosed (PD) lung, breast, and colorectal cancers from March to December 2020 (pandemic period) and compared to the similar pre-pandemic period (2017\u20132019). Trend data were also collated on COVID-19 cases and deaths per 100,000 in each population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparing the pre-pandemic period to the pandemic period there were statistically significant reductions in numbers of lung (\u219323%) and colorectal (\u219315%) PD cancers in NI and numbers of breast (\u219318%) and colorectal cancer (\u219318.5%) diagnosed in the NED. In NZ there was no significant change in the number of lung (\u219110%) or breast cancers (\u21910.2%) but a statistically significant increase in numbers of colorectal cancer diagnosed (\u21915%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The impact of COVID-19 on cancer services was mitigated in NZ as services continued as usual reflecting minimal healthcare disruption and protected cancer services linked with the elimination approach adopted. The reduction in PD cases diagnosed in NED and NI were linked with higher COVID-19 rates and reflect societal restrictions which resulted in delayed patient presentation to primary and secondary care, disruption to screening and healthcare services as a result of COVID-19 infections on staff and the need to shift intensive care to COVID-19 patients. Reductions in PD cancers in NI and the NED and in particularly lung cancers in NI, highlight the need for targeted public health campaigns to identify and treat \u2018missing\u2019 patients. Protecting cancer services should be a priority in any future pandemic or systemic healthcare system disruption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-023-11216-3","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T08:02:33Z","timestamp":1690358553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland"],"prefix":"10.1186","volume":"23","author":[{"given":"Helen","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mclean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Luff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"11216_CR1","unstructured":"WHO. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19\u201311 March 2020 [Internet]. 2020 [cited 2022 Oct 25]. Available from: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020."},{"key":"11216_CR2","doi-asserted-by":"crossref","unstructured":"Mishra NTP, Das SS, Yadav S, Khan W, Afzal M, Alarifi A et al. Global impacts of pre- and post-COVID-19 pandemic: Focus on socio-economic consequences. Sensors Int [Internet]. 2020;1:100042. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666351120300425.","DOI":"10.1016\/j.sintl.2020.100042"},{"key":"11216_CR3","unstructured":"WHO. WHO Coronavirus (COVID-19). Dashboard [Internet]. 2023 [cited 2023 Mar 1]. Available from: https:\/\/covid19.who.int\/."},{"key":"11216_CR4","doi-asserted-by":"crossref","unstructured":"Gurney JK, Millar E, Dunn A, Pirie R, Mako M, Manderson J et al. The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand\u2013a country pursuing COVID-19 elimination. Lancet Reg Heal - West Pacific. 2021;10.","DOI":"10.1016\/j.lanwpc.2021.100127"},{"key":"11216_CR5","doi-asserted-by":"publisher","unstructured":"Oliu-Barton M, Pradelski BSR, Aghion P, Artus P, Kickbusch I, Lazarus JV et al. SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties. Lancet [Internet]. 2021;397(10291):2234\u20136. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(21)00978-8.","DOI":"10.1016\/S0140-6736(21)00978-8"},{"key":"11216_CR6","doi-asserted-by":"publisher","unstructured":"Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med [Internet]. 2020;172(11):756\u20138. Available from: https:\/\/doi.org\/10.7326\/M20-1133.","DOI":"10.7326\/M20-1133"},{"key":"11216_CR7","doi-asserted-by":"publisher","first-page":"106643","DOI":"10.1016\/j.ypmed.2021.106643","volume":"151","author":"TL Kortlever","year":"2021","unstructured":"Kortlever TL, de Jonge L, Wisse PHA, Seriese I, Otto-Terlouw P, van Leerdam ME, et al. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. Prev Med (Baltim). 2021;151:106643.","journal-title":"Prev Med (Baltim)"},{"key":"11216_CR8","unstructured":"Public Health Agency. Covid 19 Impact on Breast Cancer Screening Programme [Internet]. 2020. Available from: https:\/\/www.publichealth.hscni.net\/directorate-public-health\/service-development-and-screening\/breast-screeninghtm."},{"key":"11216_CR9","doi-asserted-by":"crossref","unstructured":"Eijkelboom AH, de Munck L, Lobbes MBI, van Gils CH, Wesseling J, Westenend PJ et al. Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic. Prev Med (Baltim) [Internet]. 2021;151:106602. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0091743521001869.","DOI":"10.1016\/j.ypmed.2021.106602"},{"key":"11216_CR10","doi-asserted-by":"crossref","unstructured":"Hamilton AC, Donnelly DW, Loughrey MB, Turkington RC, Fox C, Fitzpatrick D et al. Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study. Br J Cancer. 2021.","DOI":"10.1101\/2021.02.23.21252276"},{"key":"11216_CR11","doi-asserted-by":"publisher","unstructured":"Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol [Internet]. 2020;21(6):750\u20131. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(20)30265-5.","DOI":"10.1016\/S1470-2045(20)30265-5"},{"key":"11216_CR12","doi-asserted-by":"crossref","unstructured":"Gathani T, Clayton G, MacInnes E, Horgan K. The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020. Br J Cancer. 2021;124(4).","DOI":"10.1038\/s41416-020-01182-z"},{"key":"11216_CR13","doi-asserted-by":"crossref","unstructured":"Filipe MD, van Deukeren D, Kip M, Doeksen A, Pronk A, Verheijen PM et al. Effect of the COVID-19 Pandemic on Surgical Breast Cancer Care in the Netherlands: A Multicenter Retrospective Cohort Study. Clin Breast Cancer [Internet]. 2020;20(6):454\u201361. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S152682092030207X.","DOI":"10.1016\/j.clbc.2020.08.002"},{"key":"11216_CR14","doi-asserted-by":"crossref","unstructured":"Morris EJA, Goldacre R, Spata E, Mafham M, Finan PJ, Shelton J et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. Lancet Gastroenterol Hepatol [Internet]. 2021;6(3):199\u2013208. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2468125321000054.","DOI":"10.1016\/S2468-1253(21)00005-4"},{"key":"11216_CR15","doi-asserted-by":"publisher","unstructured":"CRC COVID Research Collaborative. The impact of the COVID-19 pandemic on colorectal cancer service provision. Br J Surg [Internet]. 2020;107(11):e521\u20132. Available from: https:\/\/doi.org\/10.1002\/bjs.11990.","DOI":"10.1002\/bjs.11990"},{"key":"11216_CR16","unstructured":"Rijksoverheid. Coronavirus Dashboard [Internet]. 2021. Available from: https:\/\/coronadashboard.government.nl\/landelijk\/positief-geteste-mensen."},{"key":"11216_CR17","unstructured":"Institute of Environmental Science and Research Ministry of Health - New Zealand. NZ COVID-19 Dashboard [Internet]. 2021. Available from: https:\/\/nzcoviddashboard.esr.cri.nz\/#!\/."},{"key":"11216_CR18","unstructured":"Northern Ireland Statistics and Research Agency. Coronavirus (COVID-19) Statistics [Internet]. 2021. Available from: https:\/\/www.nisra.gov.uk\/statistics\/ni-summary-statistics\/coronavirus-covid-19-statistics."},{"key":"11216_CR19","unstructured":"NICR. The impact of the COVID-19 on cancer diagnosis [Internet]. 2021 [cited 2021 Jun 21]. Available from: https:\/\/www.qub.ac.uk\/research-centres\/nicr\/Publications\/ImpactofCovid19onCancerDiagnosis\/."},{"key":"11216_CR20","doi-asserted-by":"publisher","unstructured":"McIntyre A, Ganti AK. Lung cancer\u2014A global perspective. J Surg Oncol [Internet]. 2017;115(5):550\u20134. Available from: https:\/\/doi.org\/10.1002\/jso.24532.","DOI":"10.1002\/jso.24532"},{"key":"11216_CR21","unstructured":"Ministry of Health \u2013 Manat\u016b Hauora. National Bowel Screening Programme [Internet]. 2022 [cited 2023 Jan 23]. Available from: https:\/\/www.health.govt.nz\/our-work\/preventative-health-wellness\/screening\/national-bowel-screening-programme#:~:text=The free National Bowel Screening,for screening every 2 years."},{"issue":"6","key":"11216_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/0141076820931452","volume":"113","author":"A Majeed","year":"2020","unstructured":"Majeed A, Maile EJ, Bindman AB. The primary care response to COVID-19 in England\u2019s National Health Service. J R Soc Med. 2020;113(6):208\u201310.","journal-title":"J R Soc Med"},{"key":"11216_CR23","unstructured":"Gerada C. Primary care has transformed into a \u201cdial-in\u201d or \u201cClick First\u201d service. Health Serv J. 2020;27."},{"key":"11216_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ijid.2020.11.204","volume":"103","author":"M Ludwig","year":"2021","unstructured":"Ludwig M, Jacob J, Basedow F, Andersohn F, Walker J. Clinical outcomes and characteristics of patients hospitalized for influenza or COVID-19 in Germany. Int J Infect Dis. 2021;103:316\u201322.","journal-title":"Int J Infect Dis"},{"key":"11216_CR25","unstructured":"Bannon F, McKenna H, Donnelly C, Mayock M, Harbinson A, Mathieson S et al. Pathways to a Cancer Diagnosis: Monitoring the variation in the patient journey across Northern Ireland. 2020."},{"key":"11216_CR26","first-page":"366","volume":"30","author":"M Mousavinezhad","year":"2016","unstructured":"Mousavinezhad M, Majdzadeh R, Sari AA, Delavari A, Mohtasham F. The effectiveness of FOBT vs. FIT: a meta-analysis on colorectal cancer screening test. Med J Islam Repub Iran. 2016;30:366.","journal-title":"Med J Islam Repub Iran"},{"key":"11216_CR27","doi-asserted-by":"crossref","unstructured":"Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet [Internet]. 2023;401(10374):390\u2013408. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673622016944.","DOI":"10.1016\/S0140-6736(22)01694-4"},{"key":"11216_CR28","doi-asserted-by":"publisher","unstructured":"Gourd E. Lung cancer control in the UK hit badly by COVID-19 pandemic. Lancet Oncol [Internet]. 2020;21(12):1559. Available from: https:\/\/doi.org\/10.1016\/S1470-2045(20)30691-4.","DOI":"10.1016\/S1470-2045(20)30691-4"},{"issue":"6","key":"11216_CR29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S2213-2600(20)30170-3","volume":"8","author":"L Calabr\u00f2","year":"2020","unstructured":"Calabr\u00f2 L, Peters S, Soria J-C, Di Giacomo AM, Barlesi F, Covre A, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med. 2020;8(6):542\u20134.","journal-title":"Lancet Respir Med"},{"key":"11216_CR30","unstructured":"UK Lung Cancer Coalition. COVID-19 Matters [Internet]. 2020. Available from: https:\/\/www.uklcc.org.uk\/our-reports\/october-2020\/covid-19-matters."},{"issue":"11","key":"11216_CR31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/thoraxjnl-2020-215314","volume":"75","author":"PM George","year":"2020","unstructured":"George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009\u201316.","journal-title":"Thorax"},{"key":"11216_CR32","doi-asserted-by":"publisher","unstructured":"Singh AP, Berman AT, Marmarelis ME, Haas AR, Feigenberg SJ, Braun J et al. Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncol Pract [Internet]. 2020;16(9):579\u201386. Available from: https:\/\/doi.org\/10.1200\/OP.20.00286.","DOI":"10.1200\/OP.20.00286"},{"key":"11216_CR33","doi-asserted-by":"crossref","unstructured":"Millar E, Gurney J, Beuker S, Goza M, Hamilton MA, Hardie C et al. Maintaining cancer services during the COVID-19 pandemic: the Aotearoa New Zealand experience. Lancet Reg Heal - West Pacific. 2021;11.","DOI":"10.1016\/j.lanwpc.2021.100172"},{"key":"11216_CR34","unstructured":"NICR. Impact of COVID-19 on incidence, survival and mortality of lung cancer in Northern Ireland [Internet]. 2022. Available from: https:\/\/www.qub.ac.uk\/research-centres\/nicr\/FileStore\/OfficialStats2020\/Filetoupload,1321783,en.pdf."},{"key":"11216_CR35","doi-asserted-by":"crossref","unstructured":"Monari C, Sagnelli C, Maggi P, Sangiovanni V, Numis FG, Gentile I et al. More severe COVID-19 in patients with active Cancer: results of a Multicenter Cohort Study. Front Oncol. 2021;11.","DOI":"10.3389\/fonc.2021.662746"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11216-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T08:03:22Z","timestamp":1690358602000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11216-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11216"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11216-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted on aggregate anonymised data in with data sharing agreements in place with New Zealand and the Netherlands and data is presented in accordance with Northern Ireland Cancer Registry (NICR) Confidentiality and Data Protection Policies and New Zealand\u2019s Privacy Act 2020, the Health Information Privacy Code 2020. The NICR has ethical approval from the Office for Research Ethics Committees of Northern Ireland (ORECNI) (Ref: 20\/NI\/0132, IRAS project ID: 288121), for the collection and use of routinely collected data, relating to cancer patients, within the fields of health and social care research. As such, specific ethical approval and informed consent from the data subjects were not required for this study. All methods were subject to scientific critique and all data processing and analysis was conducted in accordance with the ORECNI conditions for ethical approval to use this data. The data from New Zealand was provided at an aggregated level in adherence to New Zealand\u2019s Privacy Act 2020, the Health Information Privacy Code 2020, and the Health Information Governance Guidelines Ministry of Health, HISO 10064:2017: health information governance guidelines. Wellington, New Zealand: Ministry of Health; 2017. As such, ethical approval was not required from an ethics committee in New Zealand and the aggregate anonymous data was approved for use in line with Te Aho o Te Kahu Confidentiality and Data Protection Policies. In the Netherlands, this study did not require approval from an ethics committee according to the Central Committee on Research involving Human Subjects (CCMO). The Privacy Review Board of the Netherlands Cancer Registry approved the use of anonymous data for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"700"}}